Bladder cancer nardilisin-1 level investigation

ladder cancer (BC), It is a genitourinary system disease associated with mortality and morbidity. An ideal tumor marker has not yet been found to reduce the frequency of cystoscopy onthe BC screening. In recent years, it has been shown that nardilysin-1 is highly expressed in cancer cells such as breast, stomach and esophagus and tumor proliferation. Our aim in this study is to investigate the role of serum nardilysin-1 levels in the diagnosis and follow-up of BC. The study was composed of 49 patients with BC and 34 healthy controls. Serum nardilysin-1 level was significantly higher in patients with BC than in the control group (p = 0.000). At the same time, serum nardilysin-1 levels were significantly higher in patients with high risk assessment and pathological stage (p = 0.032, p = 0.044, respectively). Moreover, it was significantly increased in the presence of multiple tumors and in patients with tumor size > 3 cm (p = 0.040 p = 0.013 respectively). In ROC analysis, the area under the curve was found 0.748 for nardilysin-1 (p = 0,000). In the BC, systematic inflammation markers (CRP, NLR and SII) were found to be significantly higher in patients with BC(p = 0.000, p = 0.000, p = 0.000, respectively). Also, a positive correlation was found between nardilysin-1 and CRP and CAR ratio (r = 0.315, p <0.05, r = 0,2291, p <0.05). As a result, serum nardilysin-1 level indicates that it may be a potential biomarker that can be used in the diagnosis and monitoring progression response to therapy of bladder cancer.